Gulmira Alipova, Anna Bazarova, Nazira Bazarova, Rimma Bazarbekova, Gulnara Bedelbaeva, I. Guseva, Gulnara Junusbekova, Ainur Dossanova, Gulnar Jussupova, Murat Mukarov, Akmaral Nurbekova, Tatiana Oylarova, Zhannat Taubaldieva, S. Tereshchenko, Meyramgul Tundybaeva
{"title":"Клиническое значение результатов исследования DAPA HF (Dapagliflozin and prevention of adverse-outcomes in heart failure) для пациентов и врачей. Консенсус совета Экспертов","authors":"Gulmira Alipova, Anna Bazarova, Nazira Bazarova, Rimma Bazarbekova, Gulnara Bedelbaeva, I. Guseva, Gulnara Junusbekova, Ainur Dossanova, Gulnar Jussupova, Murat Mukarov, Akmaral Nurbekova, Tatiana Oylarova, Zhannat Taubaldieva, S. Tereshchenko, Meyramgul Tundybaeva","doi":"10.31082/1728-452x-2021-223-1-2-14","DOIUrl":null,"url":null,"abstract":"The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease. Keywords: chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus.","PeriodicalId":14842,"journal":{"name":"Journal \"Medicine\"","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal \"Medicine\"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31082/1728-452x-2021-223-1-2-14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Клиническое значение результатов исследования DAPA HF (Dapagliflozin and prevention of adverse-outcomes in heart failure) для пациентов и врачей. Консенсус совета Экспертов
The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease. Keywords: chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
